Volume 3.22 | Jun 15

Prostate Cell News 3.22 June 15, 2012
     In this issue: Publications | Science News | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Prostate Cell News on Twitter
TOP STORY

Paxillin Mediates Extranuclear and Intranuclear Signaling in Prostate Cancer Proliferation
Scientists demonstrated that paxillin, a known cytoplasmic adaptor protein, regulates both androgen- and EGF-induced nuclear signaling. [J Clin Invest] Full Article

[New Webinar] Discover How to Reduce Variability in Primary Neuron Cultures with NeuroCult SM

PUBLICATIONS (Ranked by impact factor of the journal)

LABORATORY RESEARCH

GRP78 Regulates Clusterin Stability, Retrotranslocation and Mitochondrial Localization Under ER Stress in Prostate Cancer
Using human prostate cancer cells, researchers showed that GRP78 associates with clusterin under endoplasmic reticulum (ER) stress conditions to facilitate its retrotranslocation and redistribution to the mitochondria. [Oncogene] Abstract

Poly[3-(3, 4-Dihydroxyphenyl) Glyceric] Acid from Comfrey Exerts Anti-Cancer Efficacy Against Human Prostate Cancer via Targeting Androgen Receptor, Cell Cycle Arrest and Apoptosis
Researchers investigated the efficacy of a novel phytochemical poly[3-(3, 4-dihydroxyphenyl)glyceric acid] from Caucasian species of comfrey (Symphytum caucasicum) and its synthetic derivative syn-2, 3-dihydroxy-3-(3, 4-dihydroxyphenyl) propionic acid against human prostate cancer LNCaP and 22Rv1 cells. [Carcinogenesis] Abstract

Co-Targeting Stress-Activated Hsp27 and Autophagy as a Combinatorial Strategy to Amplify Endoplasmic Reticular Stress in Prostate Cancer
Investigators reported that heat shock protein-27 (Hsp27) protects human prostate cancer cells against proteotoxic stress induced by proteasome inhibition, and that Hsp27 silencing using siRNA or antisense induced both apoptosis and autophagy through mechanisms involving reduced proteasome activity and induction of endoplasmic reticulum stress. [Mol Cancer Ther] Abstract

A Selective Inhibitor of the Immunoproteasome Subunit LMP2 Induces Apoptosis in PC-3 Cells and Suppresses Tumor Growth in Nude Mice
To validate the immunoproteasome as a chemotherapeutic target, an immunoproteasome catalytic subunit LMP2-targeting inhibitor and siRNA were used. The sensitivity of PC-3 prostate cancer cells to these reagents was investigated using viability assays. [Br J Cancer] Abstract

Flavonoid Ampelopsin Inhibits the Growth and Metastasis of Prostate Cancer In Vitro and in Mice
Scientists evaluated the chemopreventive effect of a novel flavonoid, ampelopsin on the growth and metastasis of prostate cancer cells. [PLoS One] Full Article

Differential Tumorigenic Potential and Matriptase Activation between PDGF B vs. PDGF D in Prostate Cancer
Investigators examined potential oncogenic functions of ß-platelet-derived growth factor (ß-PDGFR) ligands PDGF B and PDGF D, utilizing non-malignant prostate epithelial cells engineered to overexpress these ligands. [Mol Cancer Res] Abstract

Expression of TGFß3 and Its Effects on Migratory and Invasive Behavior of Prostate Cancer Cells: Involvement of PI3-kinase/AKT Signaling Pathway
Researchers carried out expression analysis of transforming growth factor-ß (TGFß) isoforms and signaling components in cell line models representing different stages of prostate cancer and studied the differential effects of specific isoforms on migratory and invasive behavior and induction of the PI3-kinase pathway. [Clin Exp Metastasis] Abstract

Androgen-Independent Prostate Cancer Cells Circumvent EGFR Inhibition by Overexpression of Alternative HER Receptors and Ligands
A potential mechanism to overcome epidermal growth factor receptor (EGFR) blockade in cancer cells is the autocrine activation of alternative receptors of the human EGFR (HER) family through the overexpression of the HER receptors and ligands. Here, researchers analyzed if this intrinsic resistance mechanism might contribute to the inefficacy of EGFR inhibitors in prostate cancer. [Int J Oncol] Abstract


CLINICAL RESEARCH

Randomized Phase II/III Study of Docetaxel with or without Risedronate in Patients with Metastatic Castration Resistant Prostate Cancer, the Netherlands Prostate Study
Researchers aimed to investigate the potential benefit of adding risedronate to docetaxel in patients with metastatic castration resistant prostate cancer. [Eur J Cancer] Abstract

Hypofractionated High-Dose Radiation Therapy for Prostate Cancer: Long-Term Results of a Multi-Institutional Phase II Trial
Scientists reported late gastrointestinal and genitourinary toxicity, biochemical and clinical outcomes, and overall survival after hypofractionated radiation therapy for prostate cancer. [Int J Radiat Oncol Biol Phys] Abstract

PCA3 Sensitivity and Specificity for Prostate Cancer Detection in Patients with Abnormal Prostate Specific Antigen and/or Suspicious Digital Rectal Examination. First Latin American Experience
Researchers described the application of the PROGENSA PCA3 assay for prostate cancer gene 3 (PCA3) detection in urine in Chilean men and its utility for prostate cancer diagnosis in men with an indication of prostate biopsy. [Urol Oncol] Abstract

Ready Sep Go - Watch the Video on RoboSep™, the Fully Automated Cell Separator

SCIENCE NEWS

Generex Announces Publication of Abstract Showing Potential of Antigen Express AE37 Immunotherapeutic Cancer Vaccine Technology in Prostate Cancer
Generex Biotechnology Corporation announced publication of an abstract demonstrating a more broad and robust immunological response in AE37 treated patients with prostate cancer than previously suspected. [Press release from Generex Biotechnology Corporation discussing research presented at the American Society of Clinical Oncology (ASCO) 2012, Chicago] Press Release

Data from a Phase II Study Continues to Show Early Activity of OGX-427 in Patients with Prostate Cancer
OncoGenex Pharmaceuticals, Inc. announced data from a Phase II study of its investigational compound OGX-427 in chemotherapy-naive metastatic castration resistant prostate cancer patients. [Press release from OncoGenex Pharmaceuticals, Inc. discussing research presented at the American Society of Clinical Oncology (ASCO) 2012, Chicago] Press Release

Clinical Data Presented on Orteronel (TAK-700) without Steroids in Non-Metastatic Prostate Cancer
Millennium: The Takeda Oncology Company and Takeda Pharmaceutical Company Limited announced updated results from a phase II study of orteronel dosed without prednisone in patients with non-metastatic castration resistant prostate cancer and rising prostate-specific antigen. [Press release from Millennium: The Takeda Oncology Company discussing research presented at the American Society of Clinical Oncology (ASCO) 2012, Chicago] Press Release

CyberKnife® Prostate SBRT Outcomes and Quality of Life Data Presented
Accuray Incorporated announced outcome data on intermediate risk prostate cancer patients treated with CyberKnife® Prostate stereotactic body radiation therapy (SBRT). [Press release from Accuray Incorporated discussing research presented at the American Urological Association Meeting (AUA) 2012, Atlanta]
Press Release

INDUSTRY NEWS

TeSR™-E8™ and STEMdiff™: New Products to Advance Research on Human Pluripotent Stem Cells
STEMCELL Technologies Inc. announced its plans to release a series of new products to advance research and translational applications for human pluripotent stem cells.
 [STEMCELL Technologies Inc.]
Press Release


Osiris Receives Second Approval for Life-Saving Stem Cell Drug; Prochymal Granted Marketing Consent by New Zealand
Osiris Therapeutics, Inc. announced it has received consent from New Zealand to market its first-in-class stem cell therapy Prochymal® (remestemcel-L), for the treatment of acute graft-vs-host disease in children. With this decision New Zealand joins Canada, which last month became the world’s first internationally recognized regulatory authority to grant approval to a stem cell drug. [Osiris Therapeutics, Inc.]
Press Release

Clinical Trial at The Cancer Institute of New Jersey Studies Combination of Vaccine and Hormone Therapy in Treatment of Prostate Cancer

Investigators at The Cancer Institute of New Jersey have partnered with the National Cancer Institute and launched a clinical trial examining the effectiveness of a combined vaccine and hormone treatment for prostate cancer that is resistant to hormone therapy and not visible on imaging tests such as a CT scan and a bone scan. [The Cancer Institute of New Jersey] Press Release

POLICY NEWS

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

EVENTS

NEW 7th Fraunhofer Life Science Symposium Leipzig 2012
November 29-30, 2012
Leipzig, Germany

Visit our events page to see a complete list of events in the prostate cell community.

JOB OPPORTUNITIES

Research Associate – Chemistry (STEMCELL Technologies, Inc.)

Research Associate – Particle Chemistry (STEMCELL Technologies, Inc.)


Research Technologist – Contract Assay Services (STEMCELL Technologies, Inc.)


Research Technologist – Media Development (STEMCELL Technologies, Inc.)

Scientist – Epithelial Cell Research (STEMCELL Technologies, Inc.)


Scientist – Induced Pluripotent Stem Cells (STEMCELL Technologies, Inc.)


Scientist – Mesenchymal Cell Research (STEMCELL Technologies, Inc.)

Scientist – hPSC Bioengineering (STEMCELL Technologies, Inc.)


Associate Research Scientist – Stem Cells and Prostate Epithelium (Columbia University Medical Center)

Clinical Research Associate – Cancer (Jennerex Biotherapeutics, Inc.)

Postdoctoral Position – Cancer Genomics (University of California)


Research Associate – Development (Precision Therapeutics, Inc.)

Recruit Top Talent:
Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or Suggestions? Email info@connexoncreative.com with your feedback.

Learn more about Prostate Cell News: Archives | Events | Contact Us